查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2007858

基因编辑技术市场预测至2034年—按类型、组件、交付方式、应用、最终用户和地区分類的全球分析

Gene Editing Technologies Market Forecasts to 2034 - Global Analysis By Type, Component, Delivery Method, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计到 2026 年，全球基因编辑技术市场规模将达到 68 亿美元，并在预测期内以 17.2% 的复合年增长率增长，到 2034 年将达到 234 亿美元。

基因编辑技术是指一系列分子生物学工具，它们能够透过在预定的基因组位点引入位点特异性的切割、缺失、插入或碱基水平的改变，对活细胞和生物体中的DNA序列进行精确且靶向的修饰。这些技术包括CRISPR-Cas核酸酶系统、活化因子样效应核酸酶、锌指核酸酶、Meganucleases、碱基编辑和先导编辑平台。透过病毒载体、脂质奈米颗粒或电穿孔等方式递送，这些技术可应用于基因治疗、功能基因体学、农业生物技术、药物研发和细胞株工程等领域。

CRISPR疗法研发管线的拓展

CRISPR治疗产品线的扩展是市场成长的驱动力，镰状细胞贫血症和β地中海贫血疗法的突破性临床核准已在商业性证明了基因编辑技术作为一种根治性治疗方法的潜力。多个涵盖肿瘤、罕见遗传疾病和感染疾病适应症的后期临床项目正在增强投资者和製药合作伙伴对商业化前景的信心。监管机构正在製定针对基因编辑的指导框架，以降低核准的不确定性，这正在加速对该产品线的投资，并扩大包括碱基编辑和先导编辑在内的下一代编辑平台的治疗目标市场。

关于非目标编辑的安全问题

脱靶编辑带来的安全隐患仍然是临床和监管方面持续存在的障碍。脱靶位点的非预期基因组修饰具有致癌性或致病风险，必须在获得监管部门核准前进行全面阐明。包括FDA在内的监管机构要求使用全基因组定序进行广泛的脱靶分析，这给临床前开发带来了沉重的成本负担。早期基因编辑临床计画中的不利事件会加剧监管审查，延长临床试验暂停后的审查期，增加开发风险溢价，并限制对新型编辑平台的商业性投资。

农业生物技术应用

随着美国、日本和阿根廷的监管机构将基因编辑作物与传统基因改造生物区分开来，并简化产品核可流程，基因编辑技术在农业生物技术领域的应用展现出巨大且快速增长的商业性机会。精准的基因编辑技术无需引入外源DNA，即可培育出抗病性、抗旱性、营养价值更高、保质期更长的作物。日益增长的粮食安全问题和应对气候变迁的迫切需求，正迫使农业相关企业加快对基因编辑研究的投资，其商业用户群也正从生物医学领域扩展到更广泛的范围。

伦理和监管方面的暂停风险

围绕着人类生殖细胞基因编辑的伦理争议以及监管机构可能采取的暂停措施，对市场发展的信心构成系统性威胁。在发生多起备受瞩目的未经授权的基因改造案例后，这种趋势尤其明显。国际监管机构和生物伦理委员会仍在就人类基因编辑的可接受界限展开辩论，由此产生的政策不确定性使长期产业计画变得复杂。关键市场的限制性立法可能导致研发禁令，这不仅会限制目标市场的范围，还可能为参与应用这些争议性编辑技术的公司带来声誉风险。

新冠疫情的影响：

新冠疫情加速了人们对基因编辑技术的认知和投资，并透过CRISPR基因编辑技术快速病毒检测诊断试剂盒的紧急监管核准，展现了其在治疗应用之外的多功能性。疫情期间对核酸递送技术（包括脂质奈米颗粒）的投资，直接推动了基因编辑疗法递送基础设施的完善。疫情后，支付方和临床医师对基因组医学的认知不断提高，促使基因编辑疗法的报销范围持续扩大。

在预测期内，基础编辑技术细分市场预计将占据最大的市场份额。

预计在预测期内，碱基编辑技术将占据最大的市场份额，因为它能够进行精确的单核苷酸替换，而不会造成双链DNA断裂，从而显着降低了与传统CRISPR-Cas核酸酶系统相关的脱靶编辑和染色体重排风险。这种卓越的安全性正在加速监管部门的核准和针对点突变引起的遗传疾病的治疗应用的临床部署。多个碱基编辑专案正在进行临床试验，形成了一个强大的后期开发平臺，推动该领域在销售方面保持主导地位。

预计试剂和耗材领域在预测期内将呈现最高的复合年增长率。

在预测期内，试剂和耗材领域预计将呈现最高的成长率，这主要得益于基因编辑工作流程在研究和临床检查室中的日益普及，从而持续推动对嚮导RNA组分、Cas蛋白试剂、检验载体试剂盒和验证检测耗材的需求。学术界和製药业在基因编辑应用整体的研究活动活性化，也带动了耗材采购量的共同成长。各机构间基因编辑研究通讯协定的日益标准化提高了耗材的可替代性，使主要试剂供应商能够从批量采购合约和规模化分销中获益。

市占率最大的地区：

在整个预测期内，北美预计将保持最大的市场份额，这得益于主导地位、基因编辑生物技术公司的集中度，以及美国国立卫生研究院（NIH）和私人企业对基础和转化基因编辑研究的大力资助。美国拥有全球大部分处于临床阶段的基因编辑计画。美国食品药物管理局（FDA）针对细胞和基因治疗产品所製定的完善法规结构，以及有利的智慧财产权保护体系，巩固了北美在基因编辑商业化领域的主导地位。

复合年增长率最高的地区：

在预测期内，亚太地区预计将呈现最高的复合年增长率，这主要得益于中国、韩国和日本基因组研究投资的快速增长、政府主导的国家基因编辑研究项目以及国内生物技术产业能力的提升。中国在CRISPR研究论文和临床应用方面取得了显着进展，政府资金大力支持国家基因组创新策略。全部区域学术和医药研究基础设施的扩展，正在推动对基因编辑研究工具、试剂和治疗药物开发服务的需求成长。

免费客製化服务：

所有购买此报告的客户均可享受以下免费自订选项之一：

  • 企业概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域细分
    • 应客户要求，我们提供主要国家和地区的市场估算和预测，以及复合年增长率（註：需进行可行性检查）。
  • 竞争性标竿分析
    • 根据产品系列、地理覆盖范围和策略联盟对主要企业进行基准分析。

目录

第一章：执行摘要

  • 市场概览及主要亮点
  • 驱动因素、挑战与机会
  • 竞争格局概述
  • 战略洞察与建议

第二章：研究框架

  • 研究目标和范围
  • 相关人员分析
  • 研究假设和限制
  • 调查方法

第三章 市场动态与趋势分析

  • 市场定义与结构
  • 主要市场驱动因素
  • 市场限制与挑战
  • 投资成长机会和重点领域
  • 产业威胁与风险评估
  • 技术与创新展望
  • 新兴市场/高成长市场
  • 监管和政策环境
  • 新冠疫情的影响及復苏前景

第四章：竞争环境与策略评估

  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争公司之间的竞争
  • 主要企业市占率分析
  • 产品基准评效和效能比较

第五章：全球基因编辑技术市场：按类型划分

  • CRISPR-Cas系统
  • TALEN（转录活化因子样效应核酸酶）
  • 锌指核酸酶（ZFN）
  • Meganucleases
  • 基础编辑技术
  • 进阶编辑技术
  • 其他技术类型

第六章 全球基因编辑技术市场：依组件划分

  • 试剂和耗材
  • 装置
  • 软体和生物资讯学工具
  • 服务
  • 成套工具
  • 酵素
  • 其他规则

第七章 全球基因编辑技术市场：以交付方式划分

  • 病毒载体
  • 非病毒载体
  • 电穿孔
  • 显微注射
  • 脂质奈米颗粒
  • 实体交付方式
  • 其他配送方式

第八章 全球基因编辑技术市场：依应用领域划分

  • 基因治疗
  • 农业生物技术
  • 药物发现与开发
  • 功能基因体学
  • 细胞株工程
  • 诊断发展
  • 其他用途

第九章 全球基因编辑技术市场：依最终用户划分

  • 生技公司
  • 製药公司
  • 学术研究机构
  • 受託研究机构（CRO）
  • 农业相关企业
  • 临床研究中心
  • 其他最终用户

第十章 全球基因编辑技术市场：依地区划分

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 比利时
    • 瑞典
    • 瑞士
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 马来西亚
    • 新加坡
    • 越南
    • 其他亚太国家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
    • 智利
    • 秘鲁
    • 其他南美国家
  • 世界其他地区（RoW）
    • 中东
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 以色列
      • 其他中东国家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲国家

第十一章 策略市场资讯

  • 工业价值网络和供应链评估
  • 空白区域和机会地图
  • 产品演进与市场生命週期分析
  • 通路、经销商和打入市场策略的评估

第十二章 产业趋势与策略倡议

  • 併购
  • 伙伴关係、联盟和合资企业
  • 新产品发布和认证
  • 扩大生产能力和投资
  • 其他策略倡议

第十三章：公司简介

  • CRISPR Therapeutics AG
  • Editas Medicine
  • Intellia Therapeutics
  • Sangamo Therapeutics
  • Caribou Biosciences
  • Beam Therapeutics
  • Precision BioSciences
  • Horizon Discovery Group plc
  • Lonza Group AG
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Agilent Technologies, Inc.
  • Danaher Corporation
  • GenScript Biotech Corporation
  • Integrated DNA Technologies（IDT）
  • Takara Bio Inc.
  • New England Biolabs
  • Bluebird Bio, Inc.
Product Code: SMRC34762

According to Stratistics MRC, the Global Gene Editing Technologies Market is accounted for $6.8 billion in 2026 and is expected to reach $23.4 billion by 2034 growing at a CAGR of 17.2% during the forecast period. Gene editing technologies refer to a suite of molecular biology tools that enable precise, targeted modification of DNA sequences within living cells and organisms by introducing site-specific cuts, deletions, insertions, or base-level alterations at predetermined genomic loci. They include CRISPR-Cas nuclease systems, transcription activator-like effector nucleases, zinc finger nucleases, meganucleases, base editing, and prime editing platforms. Delivered via viral vectors, lipid nanoparticles, or electroporation, these technologies serve gene therapy, functional genomics, agricultural biotechnology, drug discovery, and cell line engineering applications.

Market Dynamics:

Driver:

CRISPR Therapeutic Pipeline Growth

CRISPR therapeutic pipeline growth is the primary market driver as landmark clinical approvals for sickle cell disease and beta-thalassemia treatments have commercially validated gene editing technology as a curative intervention modality. Multiple late-stage clinical programs across oncology, rare genetic diseases, and infectious disease indications are generating investor and pharmaceutical partner confidence in the commercial pathway. Regulatory agencies are developing gene editing-specific guidance frameworks that reduce approval uncertainty, accelerating pipeline investment and broadening the therapeutic addressable market for next-generation editing platforms including base and prime editing.

Restraint:

Off-target Editing Safety Concerns

Off-target editing safety concerns represent a persistent clinical and regulatory barrier as unintended genomic modifications at non-target loci carry carcinogenic or pathological risk that must be comprehensively characterized before regulatory approval. Regulators including the FDA require extensive off-target analysis using whole-genome sequencing, creating significant preclinical development cost burdens. Adverse events in early gene editing clinical programs have heightened regulatory scrutiny and extended clinical hold review timelines, increasing development risk premiums and constraining commercial investment in novel editing modality platforms.

Opportunity:

Agricultural Biotechnology Applications

Agricultural biotechnology applications represent a large and growing commercial opportunity for gene editing technologies as regulatory agencies in the United States, Japan, and Argentina distinguish gene-edited crops from traditional genetically modified organisms, streamlining product approval pathways. Precision gene editing enables development of crops with enhanced disease resistance, drought tolerance, improved nutritional profiles, and extended shelf lives without introducing foreign DNA. Growing food security concerns and climate change adaptation demands are compelling agricultural companies to accelerate gene editing research investment, expanding the commercial user base beyond biomedical applications.

Threat:

Ethical and Regulatory Moratoria Risks

Ethical controversies and potential regulatory moratoria on human germline gene editing represent systemic threats to market development confidence, particularly following high-profile incidents involving non-consented heritable genomic modifications. International regulatory bodies and bioethics commissions continue debating permissible boundaries for human gene editing applications, creating policy uncertainty that complicates long-term commercial planning. Restrictive legislative responses in major markets could impose development prohibitions that limit addressable market scope and generate reputational risks for companies associated with contested editing applications.

Covid-19 Impact:

COVID-19 accelerated gene editing technology awareness and investment as CRISPR-based diagnostic assays for rapid viral detection received emergency regulatory authorizations, demonstrating versatility beyond therapeutic applications. Pandemic-era investments in nucleic acid delivery technologies including lipid nanoparticles directly advanced gene editing therapeutic delivery infrastructure. Post-pandemic, increased genomic medicine awareness among payers and clinicians has sustainably expanded reimbursement openness for gene editing therapeutic applications.

The base editing technologies segment is expected to be the largest during the forecast period

The base editing technologies segment is expected to account for the largest market share during the forecast period, due to its ability to introduce precise single-nucleotide changes without creating double-strand DNA breaks, substantially reducing the off-target editing and chromosomal rearrangement risks associated with conventional CRISPR-Cas nuclease systems. This superior safety profile is accelerating regulatory acceptance and clinical adoption for therapeutic applications targeting point mutation-driven genetic diseases. Multiple base editing programs have entered clinical trials, generating a robust late-stage pipeline that is driving segment revenue leadership.

The reagents & consumables segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the reagents & consumables segment is predicted to witness the highest growth rate, driven by expanding research and clinical laboratory adoption of gene editing workflows that generate recurring demand for guide RNA components, Cas protein reagents, delivery vehicle kits, and validation assay consumables. Growing academic and pharmaceutical research activity across gene editing applications is generating compound volume growth in consumable procurement. Standardization of gene editing research protocols across institutions is increasing consumable substitutability, enabling volume purchasing agreements and distribution scale advantages for major reagent suppliers.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to leadership in CRISPR therapeutic development, concentration of gene editing biotechnology companies, and robust NIH and private venture funding supporting basic and translational gene editing research. The United States hosts the majority of clinical-stage gene editing programs globally. Established FDA regulatory frameworks for cell and gene therapy products, combined with favorable intellectual property protection infrastructure, sustain North America's dominant position in gene editing commercialization activity.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly expanding genomic research investment in China, South Korea, and Japan, government-backed national gene editing research programs, and growing domestic biotechnology industry capabilities. China has made significant progress in CRISPR research publications and clinical applications, with government funding substantially supporting national genomic innovation strategies. Expanding academic and pharmaceutical research infrastructure across Asia Pacific is generating rising demand for gene editing research tools, reagents, and therapeutic development services.

Key players in the market

Some of the key players in Gene Editing Technologies Market include CRISPR Therapeutics AG, Editas Medicine, Intellia Therapeutics, Sangamo Therapeutics, Caribou Biosciences, Beam Therapeutics, Precision BioSciences, Horizon Discovery Group plc, Lonza Group AG, Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies, Inc., Danaher Corporation, GenScript Biotech Corporation, Integrated DNA Technologies (IDT), Takara Bio Inc., New England Biolabs, and Bluebird Bio, Inc..

Key Developments:

In March 2026, GenScript Biotech Corporation expanded its gene editing services platform with new base and prime editing guide RNA design and synthesis capabilities targeting pharmaceutical and academic customers.

In February 2026, Beam Therapeutics reported durable clinical response data from its base editing gene therapy program for sickle cell disease at a major hematology medical conference.

In January 2026, Intellia Therapeutics initiated a Phase III pivotal study of its in vivo CRISPR-based gene editing therapy for hereditary angioedema following positive Phase II efficacy results.

In November 2025, Thermo Fisher Scientific Inc. launched an expanded CRISPR gene editing reagent portfolio including optimized high-fidelity Cas9 variants for reduced off-target genomic modification in therapeutic applications.

Types Covered:

  • CRISPR-Cas Systems
  • TALEN (Transcription Activator-Like Effector Nucleases)
  • Zinc Finger Nucleases (ZFNs)
  • Meganucleases
  • Base Editing Technologies
  • Prime Editing Technologies
  • Other Technology Types

Components Covered:

  • Reagents & Consumables
  • Instruments
  • Software & Bioinformatics Tools
  • Services
  • Kits
  • Enzymes
  • Other Components

Delivery Methods Covered:

  • Viral Vectors
  • Non-viral Vectors
  • Electroporation
  • Microinjection
  • Lipid Nanoparticles
  • Physical Delivery Methods
  • Other Delivery Methods

Applications Covered:

  • Gene Therapy
  • Agricultural Biotechnology
  • Drug Discovery & Development
  • Functional Genomics
  • Cell Line Engineering
  • Diagnostics Development
  • Other Applications

End Users Covered:

  • Biotechnology Companies
  • Pharmaceutical Companies
  • Academic & Research Institutes
  • Contract Research Organizations (CROs)
  • Agricultural Companies
  • Clinical Research Centers
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 3032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Gene Editing Technologies Market, By Type

  • 5.1 CRISPR-Cas Systems
  • 5.2 TALEN (Transcription Activator-Like Effector Nucleases)
  • 5.3 Zinc Finger Nucleases (ZFNs)
  • 5.4 Meganucleases
  • 5.5 Base Editing Technologies
  • 5.6 Prime Editing Technologies
  • 5.7 Other Technology Types

6 Global Gene Editing Technologies Market, By Component

  • 6.1 Reagents & Consumables
  • 6.2 Instruments
  • 6.3 Software & Bioinformatics Tools
  • 6.4 Services
  • 6.5 Kits
  • 6.6 Enzymes
  • 6.7 Other Components

7 Global Gene Editing Technologies Market, By Delivery Method

  • 7.1 Viral Vectors
  • 7.2 Non-viral Vectors
  • 7.3 Electroporation
  • 7.4 Microinjection
  • 7.5 Lipid Nanoparticles
  • 7.6 Physical Delivery Methods
  • 7.7 Other Delivery Methods

8 Global Gene Editing Technologies Market, By Application

  • 8.1 Gene Therapy
  • 8.2 Agricultural Biotechnology
  • 8.3 Drug Discovery & Development
  • 8.4 Functional Genomics
  • 8.5 Cell Line Engineering
  • 8.6 Diagnostics Development
  • 8.7 Other Applications

9 Global Gene Editing Technologies Market, By End User

  • 9.1 Biotechnology Companies
  • 9.2 Pharmaceutical Companies
  • 9.3 Academic & Research Institutes
  • 9.4 Contract Research Organizations (CROs)
  • 9.5 Agricultural Companies
  • 9.6 Clinical Research Centers
  • 9.7 Other End Users

10 Global Gene Editing Technologies Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 CRISPR Therapeutics AG
  • 13.2 Editas Medicine
  • 13.3 Intellia Therapeutics
  • 13.4 Sangamo Therapeutics
  • 13.5 Caribou Biosciences
  • 13.6 Beam Therapeutics
  • 13.7 Precision BioSciences
  • 13.8 Horizon Discovery Group plc
  • 13.9 Lonza Group AG
  • 13.10 Thermo Fisher Scientific Inc.
  • 13.11 Merck KGaA
  • 13.12 Agilent Technologies, Inc.
  • 13.13 Danaher Corporation
  • 13.14 GenScript Biotech Corporation
  • 13.15 Integrated DNA Technologies (IDT)
  • 13.16 Takara Bio Inc.
  • 13.17 New England Biolabs
  • 13.18 Bluebird Bio, Inc.

List of Tables

  • Table 1 Global Gene Editing Technologies Market Outlook, By Region (2023-2034)($MN)
  • Table 2 Global Gene Editing Technologies Market Outlook, By Type (2023-2034)($MN)
  • Table 3 Global Gene Editing Technologies Market Outlook, By CRISPR-Cas Systems (2023-2034)($MN)
  • Table 4 Global Gene Editing Technologies Market Outlook, By TALEN (Transcription Activator-Like Effector Nucleases) (2023-2034)($MN)
  • Table 5 Global Gene Editing Technologies Market Outlook, By Zinc Finger Nucleases (ZFNs) (2023-2034)($MN)
  • Table 6 Global Gene Editing Technologies Market Outlook, By Meganucleases (2023-2034)($MN)
  • Table 7 Global Gene Editing Technologies Market Outlook, By Base Editing Technologies (2023-2034)($MN)
  • Table 8 Global Gene Editing Technologies Market Outlook, By Prime Editing Technologies (2023-2034)($MN)
  • Table 9 Global Gene Editing Technologies Market Outlook, By Other Technology Types (2023-2034)($MN)
  • Table 10 Global Gene Editing Technologies Market Outlook, By Component (2023-2034)($MN)
  • Table 11 Global Gene Editing Technologies Market Outlook, By Reagents & Consumables (2023-2034)($MN)
  • Table 12 Global Gene Editing Technologies Market Outlook, By Instruments (2023-2034)($MN)
  • Table 13 Global Gene Editing Technologies Market Outlook, By Software & Bioinformatics Tools (2023-2034)($MN)
  • Table 14 Global Gene Editing Technologies Market Outlook, By Services (2023-2034)($MN)
  • Table 15 Global Gene Editing Technologies Market Outlook, By Kits (2023-2034)($MN)
  • Table 16 Global Gene Editing Technologies Market Outlook, By Enzymes (2023-2034)($MN)
  • Table 17 Global Gene Editing Technologies Market Outlook, By Other Components (2023-2034)($MN)
  • Table 18 Global Gene Editing Technologies Market Outlook, By Delivery Method (2023-2034)($MN)
  • Table 19 Global Gene Editing Technologies Market Outlook, By Viral Vectors (2023-2034)($MN)
  • Table 20 Global Gene Editing Technologies Market Outlook, By Non-viral Vectors (2023-2034)($MN)
  • Table 21 Global Gene Editing Technologies Market Outlook, By Electroporation (2023-2034)($MN)
  • Table 22 Global Gene Editing Technologies Market Outlook, By Microinjection (2023-2034)($MN)
  • Table 23 Global Gene Editing Technologies Market Outlook, By Lipid Nanoparticles (2023-2034)($MN)
  • Table 24 Global Gene Editing Technologies Market Outlook, By Physical Delivery Methods (2023-2034)($MN)
  • Table 25 Global Gene Editing Technologies Market Outlook, By Other Delivery Methods (2023-2034)($MN)
  • Table 26 Global Gene Editing Technologies Market Outlook, By Application (2023-2034)($MN)
  • Table 27 Global Gene Editing Technologies Market Outlook, By Gene Therapy (2023-2034)($MN)
  • Table 28 Global Gene Editing Technologies Market Outlook, By Agricultural Biotechnology (2023-2034)($MN)
  • Table 29 Global Gene Editing Technologies Market Outlook, By Drug Discovery & Development (2023-2034)($MN)
  • Table 30 Global Gene Editing Technologies Market Outlook, By Functional Genomics (2023-2034)($MN)
  • Table 31 Global Gene Editing Technologies Market Outlook, By Cell Line Engineering (2023-2034)($MN)
  • Table 32 Global Gene Editing Technologies Market Outlook, By Diagnostics Development (2023-2034)($MN)
  • Table 33 Global Gene Editing Technologies Market Outlook, By Other Applications (2023-2034)($MN)
  • Table 34 Global Gene Editing Technologies Market Outlook, By End User (2023-2034)($MN)
  • Table 35 Global Gene Editing Technologies Market Outlook, By Biotechnology Companies (2023-2034)($MN)
  • Table 36 Global Gene Editing Technologies Market Outlook, By Pharmaceutical Companies (2023-2034)($MN)
  • Table 37 Global Gene Editing Technologies Market Outlook, By Academic & Research Institutes (2023-2034)($MN)
  • Table 38 Global Gene Editing Technologies Market Outlook, By Contract Research Organizations (CROs) (2023-2034)($MN)
  • Table 39 Global Gene Editing Technologies Market Outlook, By Agricultural Companies (2023-2034)($MN)
  • Table 40 Global Gene Editing Technologies Market Outlook, By Clinical Research Centers (2023-2034)($MN)
  • Table 41 Global Gene Editing Technologies Market Outlook, By Other End Users (2023-2034)($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.